Should You Buy Novartis AG Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Novartis AG (NVS) sits in the bottom tier of our quality coverage with a score of 2.8/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $138.62.
The short answer: 2 of 2 CirclFi valuation models project upside for Novartis AG (NVS) at $138.62 — the model consensus leans bullish, with a Quality Score of 2.8/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Novartis AG (NVS) in 2026?
What Is the Bull Case vs the Bear Case for Novartis AG (NVS)?
| Bull case — $285.67 target (+106.1%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +80.1% across 2 bullish models from the current price of $138.62. | No active model flags significant downside for NVS. The low Value Trap score paints a constructive picture. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $285.67 (+106.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Novartis AG's revenue and margin trajectory in the Drug Manufacturers - General space. | |
| The company's $263.5B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does NVS Compare to Its Drug Manufacturers - General Peers?
Valuation data pages: MDCX · NSRX · MIRA · GILD · SCLX · MRK · NVO · AMGN · OGN
Which Other Stocks Score Like NVS on Quality?
Closest companies to NVS’s Quality of Company score of 2.8/10, across all industries.
- ICLR — ICON Public Limited Company (QOC 2.8) · analysis
- RYOJ — rYojbaba Co., Ltd. (QOC 2.8) · analysis
- TWG — Top Wealth Group Holding Limited (QOC 2.8) · analysis
- ACCL — Acco Group Holdings Limited (QOC 2.8) · analysis
- BTG — B2Gold Corp. (QOC 2.8) · analysis
- ESLT — Elbit Systems Ltd. (QOC 2.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Novartis AG (NVS) Worth Buying in 2026?
Novartis AG at $138.62 presents what our engine identifies as a high-conviction opportunity: 2 of 2 models see upside, quality stands at 2.8/10, and the median fair value of $249.66 implies +80.1% return potential. Investors should verify this thesis against their own risk parameters and time horizon.
These are quantitative model outputs, not investment recommendations. Novartis AG's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About NVS Stock?
Should I buy NVS stock right now?
Based on CirclFi's multi-model analysis, 2 of 2 models see upside for NVS at $138.62. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 2.8/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Novartis AG?
Key risks include: a below-average Quality Score of 2.8/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does NVS compare to its competitors?
Among Drug Manufacturers - General peers, NVS holds a Quality Score of 2.8/10. Comparable companies include MDCX (QOC 3.9), NSRX (QOC 2.7), MIRA (QOC 4.7). The relative ranking helps investors identify whether NVS offers better fundamental quality than alternatives in the same sector.
Is NVS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NVS's Quality Score of 2.8/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy NVS at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $213.66 to $285.67. At $138.62, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for NVS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad